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The ﬁbroblast growth factor receptor (FGFR) family consists of four members, named FGFR1, 2, 3, and 4. All 4 FGFRs and their
ligands, ﬁbroblast growth factors (FGFs), are expressed in colorectal cancer (CRC). Recent studies have shown that FGFR2 plays
important roles in cancer progression; therefore, it is of great interest as a novel target for cancers. Expression of FGFR2 regulates
migration, invasion, and growth in CRC. Expression of the FGFR2 isoform FGFR2 IIIb was associated with well-diﬀerentiated
histological types, and its speciﬁc ligand, FGF7, enhanced angiogenesis and adhesion to type-IV collagen via FGFR2 IIIb in CRC.
FGFR2 IIIc is detected in CRC, but its roles have not been well elucidated. Interactions between FGFR2 IIIb and IIIc and FGFs may
play important roles in CRC via autocrine and/or paracrine signaling. Several kinds of molecular-targeting agents against FGFR2
have been developed; however, it is not clear how a cancer treatment can most eﬀectively inhibit FGFR2 IIIb or FGFR2 IIIc, or
both isoforms. The aim of this paper is to summarize the roles of FGFR2 and its isoforms in CRC and clarify whether they are
potent therapeutic targets for CRC.
1.Introduction
Colorectal cancer (CRC) is the second leading cause of death
from cancer in the USA [1] and one of the most serious
causes of death from cancer in the world. The prognosis
remains poor, especially for patients with advanced or recur-
rent states of CRC. To improve the survival rates of patients
with advanced stages, several types of anticancer, molecular-
targetedagentshavebeendevelopedandarecurrentlyunder-
going clinical trials [2].
Theﬁbroblastgrowthfactors(FGFs)areheparin-binding
growth factors and are classiﬁed as FGF-1 to FGF-23 [3–5].
Human FGFs, which comprise ∼150–300 amino acids, have
ac o n s e r v e d∼120 amino acid residue core, containing ∼30–
60% amino acid identity [4]. Patients with CRC have been
reported to overexpress FGF-1 (acidic FGF), FGF-2 (basic
FGF),FGF-3,FGF-7(keratinocytegrowthfactor/KGF),FGF-
9, FGF-10, FGF-18, FGF-19, and FGF-20. FGFs exert their
biological activities by binding to high-aﬃnity tyrosine
kinase FGF receptors (FGFRs) on the surface of cells and
low-aﬃnity heparan sulfate proteoglycans that enhance lig-
andpresentation[4].FGFRsconsistoffourmembers,named
FGFR1,2,3,and4,thatareencodedbydistinctgenes.FGFRs
aresingletransmembranereceptors,containingextracellular,
transmembrane,andintracellulardomains.Theextracellular
domainofFGFRsisusuallycomposedof3immunoglobulin-
like domains (I-III). Alternative splicing of the C-terminal
halfofthethirdIg-likedomaingeneratestheIIIbandIIIciso-
forms in FGFRs1-3, but FGFR4 does not possess such alter-
nativeexons.TherearereportsofFGFRs1–4beingexpressed
in CRC [6–11]. The FGF/FGFR family plays important
roles in development and diﬀerentiation in normal human
tissues, and the family is deeply involved in carcinogenesis
and cancer progression in an autocrine or paracrine manner.
Recent studies have shown that gene ampliﬁcation,
abnormal activation, or single nucleotide polymorphisms
(SNPs) of FGFR2 play important roles in cancer progression
[12–16]; therefore, FGFR2 has been recognized as a novel
therapeutic target for cancers [17]. The aim of this paper is
to summarize the roles of FGFR2 and its isoforms in CRC2 Pathology Research International
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Figure 1: Alternative splicing of FGFR2 and speciﬁc ligands of each variant. The two FGFR2 isoforms are generated by alternative splicing
of exons 8 and 9. This alternative splicing determines the speciﬁc ligands for each FGFR2 isoform [19]. FOX-2 or ESRP1 and 2 bind to the
ISE/ISS-3 element to enhance splicing of exon 8 and silencing of exon 9.
and clarify whether they are potential therapeutic targets for
CRC.
2. Structure of FGFR2 and Its Isoforms
An important feature and mode of regulation of FGFR2
functions is that structural variants of FGFR2 are generated
by numerous alternative gene splicing events. These alterna-
tive splicing events of FGFR2 pre-mRNA generate mature
mRNA, which encodes proteins altered in both the extracel-
lular and intracellular regions. To date, more than 20 alter-
native splicing variants of FGFR2 have been identiﬁed [18].
The major splicing event occurs in the carboxyl terminal
half of the third Ig-like domain (D3). The two types of
FGFR2 isoforms are generated by alternative splicing of
exons 8 and 9. When the C-terminal half of D3 is encoded
by exon 8, the FGFR2 IIIb isoform is generated; while the
FGFR2 IIIc isoform is generated when the C-terminal half
o fD 3i se n c o d e db ye x o n9( Figure 1)[ 19]. The Intronic
Splicing Enhancer/Intronic Splicing Silencer-3 (ISE/ISS-3),
whichislocatedinintron8downstreamofaUGCAUGmotif
of FGFR2, regulates the FGFR2 splicing [20] via binding of
FOX-2 [21] or Epithelial Splicing Regulatory Protein (ESRP)
1and2[22].TheISE/ISS-3functionsspeciﬁcallyinepithelial
cell types to enhance splicing of the upstream exon 8 and
silencing of the downstream exon 9 [23]. Tissue-speciﬁc
inclusion of either exon 8 or 9 generates either the epithelial
cell-speciﬁc IIIb or mesenchymal cell-speciﬁc IIIc isoforms
[24]. Subsequently, this alternative splicing determines the
speciﬁc ligands for each FGFR2 isoform. FGF-1, 3, 7, 10, and
22 are reported to bind to FGFR2 IIIb; while FGF-1, 2, 4,
6, 9, 17, and 18 bind to FGFR2 IIIc with high aﬃnity [19,
25, 26]. FGF-FGFR binding activates intracellular signaling
cascades. Mitogenic signaling is mediated through tyrosine
phosphorylationofkeysubstrates,includingactivationofthe
mitogen-activatedproteinkinases,suchasERK-1andERK-2
via the ras pathway [27, 28].
The other major splicing of FGFR2 occurs in the
sequence encoding the intracytoplasmic carboxyl terminus
of FGFR2 IIIb. Three splice variants of FGFR2 IIIb have
been identiﬁed. The variants are named C1, C2, and C3, and
each has a diﬀerent carboxyl-terminal sequence [29]. The
C2-type carboxyl terminus is 34 amino acids shorter than
the C1-type carboxyl terminus, and the C3-type carboxyl
terminusis19aminoacidsshorterthantheC2-typecarboxyl
terminus. These sequence diﬀerences result in distinct reten-
tion of tyrosine residues that may serve as sites for receptor
autophosphorylation and docking sites for the cytoplasmic
signaling proteins of FGFR2 IIIb. The FGFR2 IIIb-C3
isoform lacks the putative phospholipase Cγ (PLCγ) binding
site.
3. Expressionand Roles of FGFR2in
Various Cancers
There are many published reports concerning the expression
of FGFR2 in various cancers. Previous reports have shown
overexpression of the C3 isoform in gastric cancer cell lines
[29] and the C2 and C3 isoforms in breast cancer cell lines
[30, 31], suggesting that aberrant expression of C2 or C3
splicing variants may contribute to cancer development.
Anomalous FGF signaling is associated with cancer
development and progression. Gene ampliﬁcation or mis-
sense mutations of FGFR2 occur in gastric, lung, breast,
ovarian, and endometrial cancers and melanomas [8, 15, 18,
32–35]. SNPs of intron 2 in FGFR2 are associated with an
increased risk of breast and endometrial cancers [12–14].
Furthermore, activating mutations of FGFR2 have been
identiﬁed in approximately 10% of endometrial cancers, and
inhibition of activated mutations of FGFR2 induced apopto-
sisandgrowthinhibitionofendometrialcarcinomacells[15,
16]. In contrast, loss-of-function mutations of FGFR2 have
been reported in melanomas [35]. These ﬁndings suggest
that FGFR2 can play a context-dependent, opposing roles in
various cancers.
A class switch from FGFR2 IIIb to FGFR2 IIIc is related
to the progression of prostate cancers [36]. Furthermore,
FGFR2 IIIc expression in prostate and bladder cancer cells
induced epithelial-mesenchymal transition (EMT) and a
switch in splicing, which may play crucial roles in cancerPathology Research International 3
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Figure 2: Immunohistochemical images of FGFR2 and its isoforms FGFR2 IIIb and FGFR2 IIIc in CRC. FGFR2 was expressed in the surface
area of crypts in a nontumorous lesion obtained from CRC tissue (arrows). FGFR2 was also expressed in ﬁbroblasts, inﬂammatory cells,
and vascular endothelium (arrowheads). CRC cells exhibited marked expression of FGFR2 in the cell membrane and cytoplasm. Isoforms of
FGFR2, FGFR2 IIIb, and FGFR2 IIIc were expressed in CRC cells. Original magniﬁcation: upper left panel, ×200; other panels, ×600.
metastasis [37–39]. We previously reported that the expres-
sion levels of FGFR2 positively correlated with the presence
of precancerous lesions in the uterine cervix, termed cervical
intraepithelial neoplasia (CIN). Furthermore, stable trans-
fection of FGFR2 IIIc in cervical cancer cell lines induced
cancer cell growth [40]. Therefore, FGFR2 IIIc correlates
with the carcinogenesis and aggressive growth of cervical
cancer.
Incontrast,therolesoftheFGFR2IIIbisoformhavebeen
controversial. Overexpression of the FGFR2 IIIb isoform,
also known as keratinocyte growth factor receptor, has been
reported in various cancers, including breast, endometrial,
cervical, lung, esophageal, gastric, pancreatic, and CRC [10,
41–51]. We reported that expression of FGFR2 IIIb and one
of its major ligands, FGF7, correlated with venous invasion,
vascular endothelial growth factor A (VEGF-A) expression,
and a poor prognosis and may promote venous invasion and
tumor angiogenesis in pancreatic cancers [49]. Pancreatic
cancer patients with high FGFR2 expression had a shorter
survival time compared to those with low FGFR2 expression.
Another ligand for FGFR2 IIIb, FGF10, induced pancreatic
cancer cell migration and invasion via FGFR2 IIIb [52]. In
contrast, decreased expression of FGFR2 IIIb in gastric can-
cer cells was associated with the proliferation and invasion of
gastric cancer cells and a poor prognosis for the patient [47].
In esophageal cancers, FGFR2 IIIb expression correlated
with a well-diﬀerentiated cell type, and FGF7 induced cell
proliferation in FGFR2 IIIb positive cancer cells [10]. The
diﬀerentrolesofFGFR2IIIbinvariouscancershavenotbeen
well characterized; however, diﬀerences may be due to the
aﬃnity of diﬀerent ligands for FGFR2 IIIb or eﬀects from
other FGFRs.
4. Expressionand Roles of FGFR2in CRC
Immunohistochemical analysis has demonstrated that
FGFR2 is expressed in the diﬀerentiated cells located on the
upper portion of the intestinal crypt in normal colorectal
epithelium (Figure 2, arrows) [53] and is related to the
proliferation and diﬀerentiation of cells [10, 54]. In patients
with CRC, expression of FGFR2 protein was observed in the
cell membrane and cytoplasm of cancer cells (Figure 2). The
mRNA of several FGFs, including FGF2, 8, 9, and 18, was
expressed in CRC cell lines and was detected by RT-PCR
analysis (Table 1)[ 49]; therefore, FGFs/FGFRs may regulate
CRC cell growth in an autocrine manner. Recently, we
reported that the invasive front of CRC cells exhibited
stronger FGFR2 expression than the surface or central area
of the cancerous cells [53]. Decreased expression of FGFR2
in CRC cells was associated with inhibited cell migration,
invasion, and tumor growth in vitro and in vivo [53].
Thus, FGFR2 plays important roles in CRC progression in
correlation with tumor cell migration, invasion, and growth
(Table 2).
Overexpression of the FGFR2 isoform FGFR2 IIIb in
CRC was associated with a well-diﬀerentiated histological
type [10, 55]. As determined by in situ hybridization, both
FGFR2 IIIband FGF7 mRNAareexpressed in CRC cells,and4 Pathology Research International
Table 1: Expression of FGFs in CRC cell lines.
FGF1 FGF2 FGF4 FGF6 FGF8 FGF9 FGF17 FGF18
DLD-1 − + −−+ −−+
HCT-15 − + −−++− +
SW480 −−−−++− +
LoVo − + −−++−−
Colo201 −−−−++− +
Table 2: Roles of FGFR2 and its splicing variants in colorectal cancers.
Reported data Roles
FGFR2
normal located in the upper portion of the intestinal crypt [50, 54]d i ﬀerentiation, growth
cancer increased expression in the invasive front of cancer cells invasion, growth
shRNA-targeting FGFR2 suppressed cell growth [53]
FGFR2 IIIb
normal located in the upper portion of the intestinal crypt [50]d i ﬀerentiation, growth
cancer Well-diﬀerentiated types [50]d i ﬀerentiation
cancer FGF-7 induced an increase of VEGF-A [56] angiogenesis
cancer FGF7 enhanced the adhesion to type-IV collagen [57] cell attachment
cancer FGF10 increased the growth rate [51]g r o w t h
FGFR2 IIIc cancer expressed in cancer cells (the present report) not reported
FGF7 mRNA was recognized in neuroendocrine cells lying
close to CRC cells [50]. FGF7 induced an increase of VEGF-
A; thus, FGF-7 and its receptor FGFR2 IIIb may be involved
in tumor angiogenesis in CRC [56]. Furthermore, FGF7
enhances adhesion to type-IV collagen, one of the main
components of the vascular basement membrane, via down-
regulation of Integrin α2 and activation of ERK1/2 and focal
adhesion kinase (FAK) signaling pathways [57]. Coexpres-
sion of FGFR2 IIIb and FGF10 has been reported in CRC
cells, and FGF10 increased the growth rate of FGFR2 IIIb-
positive CRC cell lines [51]. These ﬁndings suggest interac-
tions of FGFR2 IIIb, FGF7, and FGF10 may play important
roles in CRC proliferation and tumor angiogenesis via
autocrine and/or paracrine manners (Table 2).
Immunohistochemical analysis, quantitative RT-PCR,
and ﬂuorescent staining determined that both FGFR2 IIIb
and FGFR2 IIIc are expressed in CRC tissues and cell lines
(Figures 2, 3,a n d4)[ 49, 58]. However, the roles of the
FGFR2 IIIc isoform in CRC are not clear and require further
examination.
5.Molecular-TargetedTherapyof
the FGFR2SignalingPathway
Several kinds of molecular-targeted therapies to the FGFR2
signaling pathway have been reported in various cancers.
In endometrial cancer cells harboring activated mutations
of FGFR2, knockdown of FGFR2 using short hairpin (sh)
RNA or treatment with a pan-FGFR inhibitor, PD173074,
caused cell cycle arrest and cell death [15]. A small molecule,
FGFR2 IIIb/18S rRNA
FGFR2 IIIc/18S rRNA
5
4
3
2
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Figure 3: Expression levels of FGFR2 IIIb and IIIc in CRC cell lines.
All5CRCcelllinesexpressedFGFR2IIIbandIIIcmRNAsatvarious
levels. Quantitative RT-PCR results were expressed as the ratio of
target to 18S rRNA, with the latter serving as an internal standard.
Gene expression levels were measured in triplicate.Pathology Research International 5
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Figure 4: Immunocytochemical analysis of FGFR2 IIIb and IIIc in CRC cell lines. A human CRC cell line, LoVo, exhibited both FGFR2 IIIb
and FGFR2 IIIc isoforms in the cell membrane and cytoplasm. The expression level of FGFR2 IIIb was weak, but IIIc was strong, which is
consistent with their mRNA levels. Original magniﬁcation, ×1000; red, FGFR2 IIIb; green, FGFR2 IIIc; blue, DAPI.
Ki23057, which inhibits autophosphorylation of FGFR2 IIIb
decreased the growth of biliary tract cancer cells [59], gastric
scirrhouscarcinomacells[60,61],andCRCcells[62]invitro
and in vivo. A recent study demonstrated that monoclonal
antibodies to FGFR2 IIIb and FGFR2 IIIc isoforms suc-
cessfully inhibited the growth of gastric tumor xenografts
[63]. A mutation in the soluble ectodomain of FGFR2 IIIc,
S252W, suppressed cell growth, angiogenesis, and metastasis
of human breast cancer and prostate cancer cell lines in vitro
and in vivo [64]. We recently reported that shRNA-targeting
FGFR2 in CRC cell lines suppressed cancer cell growth,
migration, and invasion [53]; however, no other reports have
shown the usefulness of FGFR2-targeting therapy in CRC.
The best way for cancer treatment to inhibit FGFR2 IIIb
or FGFR2 IIIc, or both isoforms, has not been determined.
It may depend on each cell line or individuals that express
diﬀerent endogenous FGFR2 levels, and other FGFRs and
FGFs. Basic research clearly indicates the eﬀectiveness of
FGFR2 as a target for CRC therapy; therefore, clinical studies
are needed to develop a novel therapeutic strategy in CRC.
6.Other FGFRs andFGFsinCRC
All four FGFRs are reportedly expressed in CRC [6–11].
FGFR1 and FGFR2 are expressed in both colorectal adeno-
mas and CRC, and expression might indicate the transfor-
mation from human colon adenoma to carcinoma [6]. Over-
expressionoftheFGFR1geneleadstolivermetastasisinCRC
[9].
FGF2 and FGF20 are implicated in embryogenesis and
tissue regeneration within the colon [65–67]. FGF2 is
expressed in submucosal tissues to induce angiogenesis,
while FGF20 is expressed in epithelial progenitor cells to
induce epithelial proliferation. Aberrant splicing and acti-
vation of cryptic splice sequences in FGFR3 have been
identiﬁed in patients with CRC [8, 68]. FGFR4 and its
speciﬁc ligand FGF19 are coexpressed in cancer cells and
induce growth via ERK and FRS2 in CRC and hepatocellular
carcinoma [69]. In human intestinal epithelial cell lines and
CRC cell lines, a soluble splice variant of FGFR4 has been
reported [70], but its roles have not been determined.
7.Molecular-TargetedTherapyto
Other FGF/FGFRSignalingPathways
Protein kinases all have a catalytic domain with a conserved
amino acid sequence and similar three-dimensional struc-
tures [71]. Protein kinases are now the most popular class
of drug target after G protein-coupled receptors [72]. Small-
molecule compounds with multiple targets have recently
been developed to overcome the recurrence of drug-resistant
tumors [73]. There are several inhibitors of FGFR1 tyrosine
kinase activity, including PD173074, SU5402, and AZD2171.
AZD2171 inhibits VEGFR2, PDGFRβ, and FGFR1 tyro-
sine kinase activity, while PD173074 and SU5402 target a
relatively narrow range of tyrosine kinases. In a mouse-
xenografted CRC tumor, combined therapy with a recom-
binant FGFR1 protein vaccine and low-dose gemcitabine
inhibited tumor growth and antiangiogenesis was present
[74]. TSU68, a multiple-receptor tyrosine kinase inhibitor
that targets FGFRs, vascular endothelial growth factor
receptor-2 (VEGFR2), and a platelet-derived growth factor
receptor (PDGFR) inhibited CRC cell growth via normal-
ization of tumor vessels [75]. Brivanib Alaninate is an orally
available, selective tyrosine kinase inhibitor that targets both
VEGFR-2 and FGFR1 [76]. ENMD-2076, a small-molecule
kinase inhibitor with activity against the Aurora kinases A
and B and several other tyrosine kinases, including VEGFR-
2, cKit, and FGFR1, inhibited tumor growth in murine
xenograft models of human CRC [77].
An anti-FGFR3 monoclonal antibody that inhibited not
onlywild-typeFGFR3,butalsovariousmutantsoftherecep-
tor, exerted potent antitumor activity against bladder carci-
noma and multiple myeloma xenografts in mice [78]. The
human single-chain variable fragment (Fv) directed against
FGFR3 blocked the proliferation of bladder carcinoma cells
in vitro and in vivo [79]. Currently, most small molecule
compounds inhibit multiple tyrosine kinases and may aﬀect
not only cancer cells but also normal cells. To develop more
selective tyrosine kinase inhibitors, monoclonal antibodies,
vaccines, and emerging technologies, such as RNA aptamers
or siRNA, will be needed to treat advanced CRC.6 Pathology Research International
8. Conclusion
FGFR2 and its isoform are highly expressed in CRC and
correlate with CRC growth, invasion, and tumor angiogen-
esis. The eﬀectiveness of FGFR2-targeting therapy for CRC
has been clearly demonstrated in vitro and in vivo in basic
research studies, more so than for other FGFs or FGFRs.
Thus, anti-FGFR2 therapies, including selective targeted
therapy to the isoforms, may be novel treatments for
advanced CRC patients.
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